Predictors for response to chemotherapy and survival in locally advanced breast cancer. This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This abstract does not include a full text ...
Neoadjuvant cisplatin-based chemotherapy plus chemoradiotherapy offers a safe, effective bladder-sparing approach with promising long-term outcomes in nonmetastatic MIBC. Median disease-free survival ...
Any regression of tumor (ART) within 12 weeks versus RECIST 1.1 response category as an intermediate endpoint to assess the activity of immune checkpoint inhibitors (ICIs) for metastatic urothelial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback